In the past 10 years, the realization that migraine is a brain disorder rather than a vascular disorder has facilitated development of various treatments, ranging from innovative immunopharmaceuticals through to neurostimulation. Many clinical trials have been successful, and such considerable progress holds promise for the coming decade of migraine treatment.
Your institute does not have access to this article
Open Access articles citing this article.
The Journal of Headache and Pain Open Access 21 March 2017
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386, 743–800 (2015).
Amin, F. M. et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol. 12, 454–461 (2013).
Maniyar, F. H., Sprenger, T., Monteith, T., Schankin, C. & Goadsby, P. J. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 137, 232–241 (2014).
Hougaard, A., Amin, F., Hauge, A. W., Ashina, M. & Olesen, J. Provocation of migraine with aura using natural trigger factors. Neurology 80, 428–431 (2013).
Akerman, S., Holland, P. & Goadsby, P. J. Diencephalic and brainstem mechanisms in migraine. Nat. Rev. Neurosci. 12, 570–584 (2011).
Goadsby, P. J., Edvinsson, L. & Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28, 183–187 (1990).
Goadsby, P. J., Edvinsson, L. & Ekman, R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. 23, 193–196 (1988).
Ho, T. W., Edvinsson, L. & Goadsby, P. J. CGRP and its receptors provide new insights into migraine pathophysiology. Nat. Rev. Neurol. 6, 573–582 (2010).
Ayata, C., Jin, H., Kudo, C., Dalkara, T. & Moskowitz, M. A. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 59, 652–661 (2006).
Tolner, E. A. et al. From migraine genes to mechanisms. Pain 156 (Suppl. 1), S64–S74 (2015).
The author has received grants and personal fees from Allergan, Amgen and eNeura, and personal fees from Ajinomoto Pharmaceuticals, Akita Biomedical, Alder Biopharmaceuticals, Autonomic Technologies, Avanir Pharmaceuticals, Cipla, CoLucid Pharmaceuticals, Dr Reddy's Laboratories, EMKinetics, Ethicon, Heptares, Lilly, NEJM Journal Watch, Pfizer, Promius Pharma, Teva, UpToDate, Wells Fargo, W. L. Gore & Associates and Zosano Pharma. He has also received personal fees for medicolegal work for individuals. He also has a patent pending for magnetic stimulation for headache.
About this article
Cite this article
Goadsby, P. Incredible progress for an era of better migraine care. Nat Rev Neurol 11, 621–622 (2015). https://doi.org/10.1038/nrneurol.2015.203
The Journal of Headache and Pain (2017)